袖状胃切除与胃旁路术后肥胖相关合并症用药停用与重启比较
该研究基于Medicare受益人群,比较腹腔镜袖状胃切除与Roux-en-Y胃旁路术后5年内糖尿病、高血压、高脂血症药物停用与重启的累积发生率。胃旁路组药物停用率略高于袖状胃切除组,而在停药患者中重启率略低于袖状胃切除组。
要点
- 胃旁路术后5年糖尿病药物停用率74.7% vs 袖状胃切除72.0%。
- 胃旁路术后5年降压药停用率53.3% vs 袖状胃切除49.4%。
- 停药患者中胃旁路术后5年重启率均略低于袖状胃切除。
核心结论
- 胃旁路相比袖状胃切除与略高的药物停用发生率和略低的药物重启发生率相关。
- 需长期试验解释减重术后药物停用与合并症缓解差异的机制和因素。
研究设计与样本
- 比较效果研究,纳入2012年1月1日至2018年12月31日接受腹腔镜袖状胃切除或Roux-en-Y胃旁路的成人Medicare受益人。
- 纳入术前6个月有糖尿病、高血压或高脂血症药物索赔及相应诊断的患者,共95 405例,女性71 348例(74.8%),平均年龄56.6(SD 11.8)岁。
- 采用工具变量生存分析估计药物停用和重启的累积发生率,数据分析于2021年2月至6月进行。
主要发现
- 糖尿病药物停用5年累积发生率:胃旁路74.7%(95%CI 74.6%-74.9%) vs 袖状胃切除72.0%(95%CI 71.8%-72.2%),共30 588例。
- 降压药停用5年累积发生率:胃旁路53.3%(95%CI 53.2%-53.4%) vs 袖状胃切除49.4%(95%CI 49.3%-49.5%),共52 081例。
- 降脂药停用5年累积发生率:胃旁路64.6%(95%CI 64.5%-64.8%) vs 袖状胃切除61.2%(95%CI 61.1%-61.3%),共35 055例。
- 停药后5年糖尿病药物重启累积发生率:胃旁路30.4%(95%CI 30.2%-30.5%) vs 袖状胃切除35.6%(95%CI 35.4%-35.9%),共19 599例。
- 停药后5年降压药重启累积发生率:胃旁路67.2%(95%CI 66.9%-67.4%) vs 袖状胃切除70.6%(95%CI 70.3%-70.9%),共21 611例。
关键数值与推荐
- 糖尿病药物停用5年累积发生率胃旁路74.7% vs 袖状胃切除72.0%。
- 降压药停用5年累积发生率胃旁路53.3% vs 袖状胃切除49.4%。
- 降脂药停用5年累积发生率胃旁路64.6% vs 袖状胃切除61.2%。
- 糖尿病药物重启5年累积发生率胃旁路30.4% vs 袖状胃切除35.6%。
- 降压药重启5年累积发生率胃旁路67.2% vs 袖状胃切除70.6%。
临床怎么用
- 对于肥胖相关合并症患者,胃旁路可能与略高的药物停用率和略低的停药后重启率相关,可结合患者情况个体化选择术式。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Sleeve gastrectomy and gastric bypass are the most common bariatric surgical procedures in the world; however, their long-term medication discontinuation and comorbidity resolution remain unclear. OBJECTIVE: To compare the incidence of medication discontinuation and restart of diabetes, hypertension, and hyperlipidemia medications up to 5 years after sleeve gastrectomy or gastric bypass. DESIGN, SETTING, AND PARTICIPANTS: This comparative effectiveness research study of adult Medicare beneficiaries who underwent laparoscopic sleeve gastrectomy or Roux-en-Y gastric bypass between January 1, 2012, to December 31, 2018, and had a claim for diabetes, hypertension, or hyperlipidemia medication in the 6 months before surgery with a corresponding diagnosis used instrumental-variable survival analysis to estimate the cumulative incidence of medication discontinuation and restart. Data analyses were performed from February to June 2021. EXPOSURES: Laparoscopic sleeve gastrectomy and laparoscopic Roux-en-Y gastric bypass. MAIN OUTCOMES AND MEASURES: The primary outcome was discontinuation of diabetes, hypertension, and hyperlipidemia medication for any reason. Among patients who discontinued medication, the adjusted cumulative incidence of restarting medication was calculated up to 5 years after discontinuation. RESULTS: Of the 95 405 patients included, 71 348 (74.8%) were women and the mean (SD) age was 56.6 (11.8) years. Gastric bypass compared with sleeve gastrectomy was associated with a slightly higher 5-year cumulative incidence of medication discontinuation among 30 588 patients with diabetes medication use and diagnosis at the time of surgery (74.7% [95% CI, 74.6%-74.9%] vs 72.0% [95% CI, 71.8%-72.2%]), 52 081 patients with antihypertensive medication use and diagnosis at the time of surgery (53.3% [95% CI, 53.2%-53.4%] vs 49.4% [95% CI, 49.3%-49.5%]), and 35 055 patients with lipid-lowering medication use and diagnosis at the time of surgery (64.6% [95% CI, 64.5%-64.8%] vs 61.2% [95% CI, 61.1%-61.3%]). Among the subset of patients who discontinued medication, gastric bypass was also associated with a slightly lower incidence of medication restart up to 5 years after discontinuation. Specifically, the 5-year cumulative incidence of medication restart was lower after gastric bypass compared with sleeve gastrectomy among 19 599 patients who discontinued their diabetes medication after surgery (30.4% [95% CI, 30.2%-30.5%] vs 35.6% [95% CI, 35.4%-35.9%]), 21 611 patients who discontinued their antihypertensive medication after surgery (67.2% [95% CI, 66.9%-67.4%] vs 70.6% [95% CI, 70.3%-70.9%]), and 18 546 patients who discontinued their lipid-lowering medication after surgery (46.2% [95% CI, 46.2%-46.3%] vs 52.5% [95% CI, 52.2%-52.7%]). CONCLUSIONS AND RELEVANCE: Findings of this study suggest that, compared with sleeve gastrectomy, gastric bypass was associated with a slightly higher incidence of medication discontinuation and a slightly lower incidence of medication restart among patients who discontinued medication. Long-term trials are needed to explain the mechanisms and factors associated with differences in medication discontinuation and comorbidity resolution after bariatric surgery.
引用
- Howard R, Chao GF, Yang J, et al. Medication Use for Obesity-Related Comorbidities After Sleeve Gastrectomy or Gastric Bypass. JAMA Surg. 2022. PMID: 35019988. doi:10.1001/jamasurg.2021.6898
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。